We just spotted a hot new biotech opportunity.
This company’s developing a MUCH cheaper alternative to a $10-$15k voluntary medical procedure. Based on my team’s research, it’s potentially just as effective.
Exciting stuff, but that alone isn’t why we’re looking at the company. After all, someone could develop a drug or medical treatment that ends up failing.
We’re looking at it because the CEO and CFO that both bought tons of stock out of nowhere.
They both bought the exact same number of shares — just over 30k — at the exact same time about 12 days ago.
Altogether, each one dropped $99,997 into the stock.
Not surprisingly, it’s already up a decent amount from when they invested.
It’s still cheap enough to be a buy, but who knows how long that’ll last.
Check out the video for the full details on this biotech opportunity…